CorMedix's Rezzayo Achieves Positive Phase III Results, Boosting Future Revenue Potential
summarizeSummary
CorMedix announced positive topline Phase III ReSPECT results for its drug candidate, REZZAYO, for prophylaxis in adult allogeneic HSCT patients. This significant clinical milestone de-risks the drug and establishes long-term revenue potential, with an sNDA filing planned for H2 2026 and a targeted launch in 2027. The company also reported Q1 2026 product sales of $24.4 million, primarily from the Melinta portfolio, which was previously disclosed in the 8-K and 10-Q filings on May 14. While DefenCath sales continue, the upcoming expiration of TDAPA reimbursement is a known factor. The positive Phase III data for Rezzayo is a major catalyst for the stock, shifting focus to regulatory approval and commercialization.
At the time of this announcement, CRMD was trading at $7.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $621.9M. The 52-week trading range was $6.13 to $17.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.